Helixgate

Helixgate

Uncategorized

Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressure

Novo Nordisk’s Q1 in four words: Pills, pricing, payments and pressure

Published

on

A million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo.

Novo’s pill had sales of 2.3 billion Danish …​ ​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Makary defends Replimune melanoma rejection again as FDA tensions build

Makary defends Replimune melanoma rejection again as FDA tensions build

Published

on

Facing increasing pressure from both industry and the White House, FDA Commissioner Marty Makary said the strong bad press against him is “corporate spin” and that the agency has “followed the science.”​ ​Read More

Continue Reading

Uncategorized

CellCentric raises $220M to get multiple myeloma pill to market

Published

on

CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options.

The 22-year-old transatlantic biotech has collected a $220 million Series D to finish its …

Continue Reading

Uncategorized

Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

Published

on

First quarter earnings continue to arrive, with analysts demanding more from cautious Pfizer and Eli Lilly expecting more revenue; the FDA taps Katherine Szarama as Vinay Prasad’s controversial FDA tenure ends; oncology veterans miss Richard Pazdur at the agency’s first adcomm in nine months; and QurAlis and Corcept Therapeutics spark renewed hope in ALS.

Continue Reading
Advertisement

Trending